(Q40441306)

20 September 2017

1 reference

title

Neuroprotective therapeutic strategies. Comparison of experimental and clinical results (English)

1 reference

20 September 2017

Neuroprotective therapeutic strategies comparison of experimental and clinical results (English)

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

10 June 2024

author name string

M. Gerlach

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7605334

10 June 2024

P. Riederer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7605334

10 June 2024

M. B. Youdim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7605334

10 June 2024

language of work or name

English

0 references

publication date

1 June 1995

1 reference

20 September 2017

29 June 1995

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7605334

full work available at URL

10 June 2024

https://api.elsevier.com/content/article/PII:000629529500051Z?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

https://api.elsevier.com/content/article/PII:000629529500051Z?httpAccept=text/plain

10 June 2024

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

10 June 2024

published in

Biochemical Pharmacology

1 reference

20 September 2017

volume

50

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

1-16

1 reference

Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease

20 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

10 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Pathology of Parkinson's Disease

10 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease

10 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Excitatory amino acids and neuropsychiatric disorders

10 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Excitatory amino acid neurotoxicity and neurodegenerative disease

10 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Reactive oxygen species and the central nervous system

10 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Altered brain metabolism of iron as a cause of neurodegenerative diseases?

10 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Oxidative stress: free radical production in neural degeneration.

10 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?

10 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology

10 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Calcium in the brain under physiological and pathological conditions

10 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

The molecular pharmacology of L-deprenyl

10 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

10 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain

10 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line

10 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

GM1 ganglioside enhances regrowth of noradrenaline nerve terminals in rat cerebral cortex lesioned by the neurotoxin 6-hydroxydopamine.

10 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice

10 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment

10 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, in the rat middle cerebral artery occlusion model

10 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Dihydrolipoate reduces neuronal injury after cerebral ischemia.

10 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats.

10 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity.

10 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions

10 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate

10 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Neuroprotective effect of memantine demonstrated in vivo and in vitro.

10 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade

10 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

10 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Effect of deprenyl on the progression of disability in early Parkinson's disease

10 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

10 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

A radical hypothesis for neurodegeneration

10 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Oxidative stress, glutamate, and neurodegenerative disorders

10 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

10 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

10 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Neurotoxicity and neuroprotection in Parkinson's disease

10 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease

10 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Oxidative stress as a cause of Parkinson's disease

10 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

MRI, brain iron and experimental Parkinson's disease

10 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation

10 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats

10 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Iron induces degeneration of nigrostriatal neurons

10 June 2024

49

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers.

10 June 2024

50

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes.

10 June 2024

52

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

10 June 2024

53

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

10 June 2024

Superoxide Dismutases

54

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis

10 June 2024

55

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Production of superoxide anions by a CNS macrophage, the microglia.

10 June 2024

56

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells.

10 June 2024

57

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1.

10 June 2024

58

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Cytotoxic Effect of Brain Macrophages on Developing.

10 June 2024

59

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells

10 June 2024

60

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages

10 June 2024

61

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Rate of cell death in parkinsonism indicates active neuropathological process

10 June 2024

65

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

10 June 2024

66

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Nitric oxide takes centre-stage with newly defined roles

10 June 2024

67

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

A novel neuronal messenger molecule in brain: the free radical, nitric oxide

10 June 2024

68

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme

10 June 2024

70

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Purification and characterization of a human NO synthase

10 June 2024

72

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Localization of nitric oxide synthase indicating a neural role for nitric oxide

10 June 2024

73

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases

10 June 2024

74

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Cytostatic elimination of syngeneic rat tumor cells in vitro by nonspecifically activated macrophages

10 June 2024

75

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells

10 June 2024

76

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Nitric oxide mediates iron release from ferritin.

10 June 2024

77

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function

10 June 2024

78

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide

10 June 2024

79

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes

10 June 2024

81

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Extracellular superoxide dismutase, nitric oxide, and central nervous system O2 toxicity

10 June 2024

82

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

10 June 2024

85

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Chronic quinolinic acid lesions in rats closely resemble Huntington's disease

10 June 2024

86

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

The quinolinic acid hypothesis in Huntington's chorea

10 June 2024

87

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Normal excretion of quinolinic acid in Huntington's disease

10 June 2024

90

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease

10 June 2024

91

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia

10 June 2024

92

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Brain quinolinic acid in Huntington's disease

10 June 2024

93

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

NMDA receptor losses in putamen from patients with Huntington's disease

10 June 2024

94

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Glutamate-evoked release of arachidonic acid from mouse brain astrocytes.

10 June 2024

95

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Excitatory amino acid receptors, second messengers and regulation of intracellular Ca2+ in mammalian neurons

10 June 2024

96

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism

10 June 2024

97

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

10 June 2024

98

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement

10 June 2024

99

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria

10 June 2024

100

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity

10 June 2024

101

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

(S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 3rd communication: effect on postischemic cerebral blood flow and metabolism, and ischemic neuronal cell death

10 June 2024

103

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Phosphate/calcium alterations in the first stages of Alzheimer's disease: Implications for etiology and pathogenesis

10 June 2024

104

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

10 June 2024

106

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases

10 June 2024

107

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Changes in Ca(2+)-binding proteins in human neurodegenerative disorders

10 June 2024

109

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus

10 June 2024

110

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

[3H]nitrendipine binding in temporal cortex in Alzheimer's and Huntington's diseases

10 June 2024

111

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

[3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.

10 June 2024

112

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

10 June 2024

113

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

10 June 2024

114

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Deprenyl is metabolized to methamphetamine and amphetamine in man

10 June 2024

115

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group

10 June 2024

116

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis

10 June 2024

118

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

10 June 2024

119

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow

10 June 2024

120

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

10 June 2024

125

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

10 June 2024

127

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Nitric oxide: a radical neurotransmitter in the central nervous system

10 June 2024

128

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Brain iron and ferritin in Parkinson's and Alzheimer's diseases.

10 June 2024

129

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Parkinson's disease: an epidemiologic method for distinguishing between symptomatic and neuroprotective treatments

10 June 2024

132

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: implications for treating neurodegenerative disorders

10 June 2024

133

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease

10 June 2024

134

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.

10 June 2024

135

1 reference

https://api.crossref.org/works/10.1016/0006-2952(95)00051-Z

10 June 2024

Identifiers

1 reference

20 September 2017

1 reference